von Tobias Borgers | Dez. 14, 2023 | Boehringer
Oxford BioTherapeuticsBI 764532 was discovered using OBT’s proprietary OGAP® platform, the world’s largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targetsOxford, UK, San Jose, Calif., 24th October 2023...
von Tobias Borgers | Dez. 7, 2023 | Boehringer
Ingelheim, Germany: SENVELGO® (velagliflozin oral solution) is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus SENVELGO® makes treating feline diabetes simple and convenient for both...
von Tobias Borgers | Nov. 23, 2023 | Boehringer
We have been using Genedata Biologics across our early biologics discovery operations for many years and are very excited to onboard the US-DMPK group as this is a major step towards having complete end-to-end digital tracking of all BI’s therapeutic candidates....
von Tobias Borgers | Nov. 23, 2023 | Boehringer
BI 764532 was discovered using OBT’s proprietary OGAP® platform, the world’s largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets Oxford, UK, San Jose, Calif., 24th October 2023 – Oxford...
von Tobias Borgers | Nov. 15, 2023 | Boehringer
German biopharmaceutical company Boehringer Ingelheim“s China arm inked a strategic cooperation agreement with Chinese high-tech company ChromX Health during the recently-concluded sixth China International Import Expo in Shanghai. German biopharmaceutical...
von Tobias Borgers | Okt. 12, 2023 | Boehringer
ROCKVILLE, Md., Oct. 06, 2023 (GLOBE NEWSWIRE) — The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2023 class in AKF’s Corporate Membership Program as a Champion-level member. Boehringer Ingelheim...
